← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Ige Therapeutics, Inc.
San Diego, CA
$7,364,494
Total funding
6
Grants
Funding over time
peak $1.7M · FY2009–19$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$7,364,494 · 6
By mechanism
R44$4,868,465 · 2
R43$2,496,029 · 4
Investigators at Ige Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Broadly neutralizing(BN) pan-IgE supersite vaccine for allergic asthma$982,439
R44 · FY2019 · AI
CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma$856,276
R44 · FY2017 · AI
CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma$853,476
R44 · FY2016 · AI
Broadly neutralizing(BN) pan-IgE supersite vaccine for allergic asthma$813,544
R44 · FY2017 · AI
Broadly neutralizing(BN) pan-IgE supersite vaccine for allergic asthma$813,544
R44 · FY2018 · AI
CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma$549,186
R44 · FY2018 · AI
Targeting Galectin-3 with novel drugs for treatment of eczema$402,036
R43 · FY2010 · AI
Targeting Galectin-3 with novel drugs for treatment of eczema$401,647
R43 · FY2009 · AI
Allergy Prevention By lgE Cytotoxic Peptide(ECP)Vaccine$307,200
R43 · FY2002 · AI
Bi-functional Therapeutics for Allergy-BFTA$300,000
R43 · FY2010 · AI
Bi-functional Therapeutics for Allergy-BFTA$300,000
R43 · FY2009 · AI
Allergy Protection by Active IgE B Cell Vaccines$299,854
R43 · FY2004 · AI
Allergy Protection by Active IgE B Cell Vaccines$253,092
R43 · FY2003 · AI
Allergy Prevention By lgE Cytotoxic Peptide(ECP)Vaccine$232,200
R43 · FY2001 · AI